Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides

Biochemical Pharmacology

Volumn 59, Issue 10, 2000, Pages 1227-1236

  Fukushima, Masakazu ^a   Suzuki, Norihiko ^a   Emura, Tomohiro ^a   Yano, Shingo ^a   Kazuno, Hideki ^a   Tada, Yukio ^a   Yamada, Yuji ^a   Asao, Tetsuji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 iodo 2' deoxyuridine; 5 trifluoromethyl 2' deoxyuridine; Competitive inhibitor; Thymidine phosphorylase; Uridine phosphorylase

Indexed keywords

2' DEOXYNUCLEOSIDE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IDOXURIDINE; PYRIMIDINE DERIVATIVE; PYRIMIDINE NUCLEOSIDE; THYMIDINE PHOSPHORYLASE; TRIFLURIDINE; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE; LIVER; MALE; MONKEY; MOUSE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RAT; RODENT; SPECIES DIFFERENCE; STOMACH CANCER; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; IDOXURIDINE; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED ICR; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PLACENTA; PYRROLIDINES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE; THYMIDINE PHOSPHORYLASE; TRIFLURIDINE; URACIL;

EID: 0034657004     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00253-7     Document Type: Article

References (43)

1. Kraut A., Yamada E.W. Cytoplasmic uridine phosphorylase of rat liver. J Biol Chem. 246:1971;2021-2030.
2. Watanabe S., Hino A., Wada K., Eliason J.F., Uchida T. Purification, cloning, and expression of murine uridine phosphorylase. J Biol Chem. 270:1995;12191-12196.
3. Desgranges C., Razaka G., Rabaud M., Bricaud H. Catabolism of thymidine in human blood platelets Purification and properties of thymidine phosphorylase . Biochim Biophys Acta. 654:1981;211-218.
4. Yoshimura A., Kuwazuru Y., Furukawa T., Yoshida H., Yamada K., Akiyama S. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta. 1034:1990;107-113.
5. Pontis H., Degerstedt G., Reichard P. Uridine and deoxyuridine phosphorylase from Ehrlich ascites tumor. Biochim Biophys Acta. 51:1961;138-147.
6. Krenitsky T.A., Barclay M., Jacquez J.A. Specificity of mouse uridine phosphorylase. J Biol Chem. 239:1964;805-812.
7. Birnie G.D., Kroeger H., Heidelberger C. Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase. Biochemistry. 2:1963;566-572.
8. Zimmerman M., Seidenberg J. Deoxyribosyl transfer. J Biol Chem. 239:1964;2618-2621.
9. Veres Z., Szabolcs A., Szinai I., Dénes G., Jeney A. Enzymatic cleavage of 5-substituted-2′-deoxyuridines by pyrimidine nucleoside phosphorylases. Biochem Pharmacol. 35:1986;1057-1059.
10. Nakayama C., Wataya Y., Meyer R.B., Santi D.V., Saneyoshi M., Ueda T. Thymidine phosphorylase Substrate specificity for 5-substituted 2′-deoxyuridines . J Med Chem. 23:1980;962-964.
11. Shirasaka T., Nagayama S., Kitano S., Maehara Y., Fujii S. Pyrimidine nucleoside phosphorylase in rodents and humans. Jpn J Cancer Chemother. 8:1981;262-269.
12. Ikenaka K., Fukushima M., Nakamura H., Okamoto M., Shirasaka T., Fujii S. Metabolism of pyrimidine nucleotides in various tissues and tumor cells from rodents. Gann. 72:1981;590-597.
13. Maehara Y., Nakamura H., Nakane Y., Kawai K., Okamoto M., Nagayama S., Shirasaka T., Fujii S. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gann. 73:1982;289-298.
14. el Kouni M.H., el Kouni M.M., Naguib F.N.M. Differences in activities and substrate specificity of human and murine pyrimidine phosphorylase Implications for chemotherapy with 5-fluoropyrimidines . Cancer Res. 53:1993;3687-3693.
15. Niedzwicki J.G., Chu S.H., el Kouni M.H., Rowe E.C., Cha S. 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem Pharmacol. 31:1982;1857-1861.
16. Pizzorno G., Yee L., Burtness B.A., Marsh J.C., Darnowski J.W., Chu M.Y.W., Chu S.H., Chu E., Leffert J.J., Handschumacher R.E., Calabresi P. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res. 4:1998;1165-1175.
17. Langen P., Etzold G., Bärwolff D., Preussel B. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil. Biochem Pharmacol. 16:1967;1833-1837.
18. Woodman P.W., Sarrif A.M., Heidelberger C. Inhibition of nucleoside phosphorylase cleavage of 5-fluoro-2′-deoxyuridine by 2,4-pyrimidinedione derivatives. Biochem Pharmacol. 29:1980;1059-1063.
19. Niedzwicki J.G., el Kouni M.H., Chu S.H., Cha S. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylase. Biochem Pharmacol. 32:1983;399-415.
20. Desgranges C., Razaka G., Rabaud M., Bricaud H., Balzarini J., De Clercq E. Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted-2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem Pharmacol. 32:1983;3583-3590.
21. Grancharov K., Mladenova J., Golovinsky E. Inhibition of uridine phosphorylase by some pyrimidine derivatives. Biochem Pharmacol. 41:1991;1769-1772.
22. Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K., Usuki K., Takaku F., Risau W., Heldin C.H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 338:1989;557-562.
23. Usuki K., Saras J., Waltenberger J., Miyazono K., Pierce G., Thomason A., Heldin C.H. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun. 184:1992;1311-1316.
24. Miyazono K., Usuki K., Heldin C.H. Platelet-derived endothelial cell growth factor. Prog Growth Factor Res. 3:1991;207-217.
25. Moghaddam A., Choudhuri R., Bicknell R. Thymidine phosphorylase/platelet-derived endothelial cell growth factor An angiogenic enzyme . Bicknell R., Lewis C.E., Ferrara N. Tumour Angiogenesis. 1997;251-260 Oxford University Press, London.
26. Takebayashi Y., Yamada K., Miyadera K., Sumizawa T., Furukawa T., Kinoshita F., Aoki D., Okumura H., Yamada Y., Akiyama S., Aikou T. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer. 32A:1996;1227-1232.
27. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M., Sawada T., Onoda N., Kato Y., Sowa M. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer. 73:1996;884-888.
28. Reynolds K., Farzaneh F., Collins W.P., Campbell S., Bourne T.H., Lawton F., Moghaddam A., Harris A.L., Bicknell R. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst. 86:1994;1234-1238.
29. O'Brien T.S., Fox S.B., Dickinson A.J., Turley H., Westwood M., Moghaddam A., Gatter K.C., Bicknell R., Harris A.L. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 56:1996;4799-4804.
30. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Comley M., Whitehouse R.M., Talbot D.C., Gatter K.C., Harris A.L. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer. 75:1997;477-481.
31. Relf M., LeJeune S., Scott P.A.E., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969.
32. Kubilus J., Lee L., Baden H.P. Purification of thymidine phosphorylase from human amniochorion. Biochim Biophys Acta. 527:1978;221-228.
33. Shirasaka T., Shimamoto Y., Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53:1993;4004-4009.
34. Tatsumi K., Fukushima M., Shirasaka T., Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-flurouracil degradation in rat liver extracts. Jpn J Cancer Res. 78:1987;748-755.
35. Miyadera K., Sumizawa T., Haraguchi M., Yoshida H., Konstanty W., Yamada Y., Akiyama S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 55:1995;1687-1690.
36. Baker B.R., Kelley J.L. Irreversible enzyme inhibitors. CLXXI. Inhibition of FUDR phosphorylase from Walker 256 rat tumor by 5-substituted uracils. J Med Chem. 13:1970;461-467.
37. Maehara Y., Sakaguchi Y., Kusumoto T., Kusumoto H., Sugimachi K. Species differences in substrate specificity of pyrimidine nucleoside phosphorylase. J Surg Oncol. 42:1989;184-186.
38. Langen P., Etzold G. Enhancement of 5-iododeoxyuridine incorporation into DNA of cat tissues in vivo by inhibition of uridine-deoxyuridine phosphorylase. Mol Pharmacol. 2:1966;89-92.
39. Rogers W.I., Hartman A.C., Palm P.E., Okstein C., Kensler C.J. The fate of 5-trifluoromethyl-2′-deoxyuridine in monkeys, dogs, mice, and tumor-bearing mice. Cancer Res. 29:1969;953-961.
40. Woodman P.W., Sarrif A.M., Heidelberger C. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′-deoxyuridine. Cancer Res. 40:1980;507-511.
41. Ansfield F.J., Ramirez G. Phase I and II studies of 2′-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep. 55:1971;205-208.
42. Liu M., Cao D., Russell R., Handschumacher R.E., Pizzorno G. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res. 58:1998;5418-5424.
43. Furukawa T., Yoshimura A., Sumizawa T., Haraguchi M., Akiyama S., Fukui K., Ishizawa M., Yamada Y. Angiogenic factor. Nature. 356:1992;668.